New Technology Expands Heart Transplant Possibilities at Montreal’s ICM
Montreal, May 1, 2026 – A groundbreaking advancement in organ preservation technology is offering renewed hope to patients awaiting heart transplants. The Institut de cardiologie de Montréal (ICM) is now utilizing the Organ Care System (OCS) Heart, a device that extends the viable time for donor hearts outside the body, potentially increasing the number of organs available for transplantation and reducing wait times. This innovation represents a significant step forward in addressing the critical shortage of donor hearts globally.
The traditional method of preserving donor hearts involves cold storage, typically allowing for only four to six hours between organ removal, and transplantation. This limited timeframe restricts the geographical reach for potential recipients and can lead to the rejection of otherwise suitable organs if a compatible match isn’t found quickly enough. The OCS Heart system addresses these limitations by maintaining the heart in a near-physiological state, continuously perfusing it with oxygenated blood and keeping it at body temperature. This allows the heart to continue to “beat and live” during transport, as described by Dr. Maxime Tremblay-Gravel, Director of the ICM’s heart and advanced heart failure transplantation program.
How the OCS Heart System Works
The OCS Heart is an ex vivo perfusion platform, meaning it maintains the organ outside of the body. Unlike traditional cold storage, which essentially pauses the heart’s metabolic processes, the OCS Heart keeps the organ functioning. The system perfuses the heart, providing it with essential nutrients and oxygen, and regulates its temperature, mimicking the conditions within the human body. This sustained viability extends the potential preservation time to eight to ten hours, significantly broadening the geographical area from which donor hearts can be sourced. As reported by Noovo Info, this expanded reach could be particularly beneficial for patients in regions with limited donor availability.
Dr. Tremblay-Gravel explained that this technology is particularly impactful for patients on the transplant list, offering access to organs that might have previously been deemed unsuitable due to logistical constraints. “It’s really excellent news for patients on the waiting list to be able to access organs that, sometimes, might simply be rejected because We find no compatible recipients locally,” he stated.
Dr. Maxime Tremblay-Gravel: A Leader in Cardiac Care
Dr. Maxime Tremblay-Gravel is a key figure in the implementation of this technology at the ICM. He holds the position of Director, Medical, Heart Transplantation and Advanced Heart Failure Program, and is a regular researcher at the institute. According to his profile on the ICM website, Dr. Tremblay-Gravel is as well a clinical researcher with the Fonds de recherche du Québec – Santé (FRQS). His extensive training includes fellowships in echocardiography and research at Stanford University, as well as advanced heart failure and transplant cardiology and cardiovascular genetics research, all completed at Stanford between 2017 and 2020. He completed his residency in adult cardiology at the University of Montreal from 2014 to 2017.
Dr. Tremblay-Gravel’s research interests encompass genetic cardiomyopathies, advanced heart failure, and heart transplantation. He has published several peer-reviewed articles, including those identified by PubMed IDs 36548481, 36531737, and 30565890.
Impact on Organ Availability and Transplantation Rates
The implementation of the OCS Heart system at the ICM addresses a critical need in the field of heart transplantation. The demand for donor hearts consistently outstrips supply, leading to lengthy wait times and, tragically, the loss of lives. According to data from the Organ Procurement and Transplantation Network (OPTN), as of April 2026, over 3,500 patients in the United States alone are awaiting heart transplants. While Canadian statistics are tracked separately, the need for organs is similarly acute.
Currently, logistical challenges prevent Quebec from accepting donor organs from west of Manitoba, limiting the pool of potential matches. The OCS Heart system has the potential to overcome this barrier, allowing for the safe and effective transport of hearts over greater distances. This expanded reach could significantly increase the number of available organs for Quebec patients and reduce the time spent on the waiting list.
Looking Ahead: Expanding Access and Refining the Technology
The ICM’s adoption of the OCS Heart system is part of a broader trend toward utilizing advanced preservation technologies to improve organ transplantation outcomes. Researchers are continually working to refine these systems and explore new methods for extending organ viability. Future developments may include personalized perfusion solutions tailored to the specific needs of each donor heart, as well as improved monitoring systems to assess organ function during transport.
The success of the OCS Heart system at the ICM could pave the way for its wider adoption at other transplant centers across Canada and internationally. This would represent a significant step toward addressing the global organ shortage and providing life-saving transplants to more patients in need.
The next step for the ICM will be to continue monitoring the outcomes of transplants performed using the OCS Heart system and to share their findings with the broader medical community. Further research will be crucial to optimize the use of this technology and to maximize its impact on patient survival rates.
Have you or a loved one been affected by the organ transplant waiting list? Share your story in the comments below, and please share this article to raise awareness about the importance of organ donation.